
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is an immuno-pharma company focused on developing therapeutics for cancers with unmet needs, viral diseases, and immune-deficiency disorders. Their flagship products, Ampligen and Alferon N Injection, have billion-dollar market potential. Despite reporting a net loss in recent quarters due to being in early and clinical development stages, AIM's decision to focus on Ampligen for the treatment of late-stage pancreatic cancer presents a high potential for success. With multiple ongoing and planned clinical trials and potential positive clinical data, there is a strong likelihood of the stock's success over the upcoming year. Furthermore, AIM's current valuation is attractive for investors looking for potential high growth in the biotech sector. However, risks to attaining the price target include potential failures in product development, regulatory approvals, and competition in the market.
Bears say
AIM ImmunoTech is heavily dependent on the success of their currently ongoing Phase 2 clinical study for Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer, which is a high-risk endeavor. Additionally, the company's balance sheet shows a concerning level of debt and their recent stock sales signal a need for cash, indicating potential financial struggles going forward. The company's market potential may be high, but it likely won't be realized for at least another 3 years.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares